BACKGROUND: Epidemiologic studies have reported inconsistent findings regarding the association between the use of angiotensin-converting-enzyme (ACE) inhibitors or angiotensin-receptor blockers and the risk of cancer. We performed a meta-analysis of observational studies to assess the association. METHODS: We searched MEDLINE, EMBASE and the Cochrane Library to identify studies through January 2011. Two evaluators independently reviewed and selected articles of cohort and case-control studies on the basis of predetermined selection criteria. RESULTS: Of 3970 screened articles, 12 cohort studies and 16 case-control studies were selected for analysis. We found no significant association between the use of ACE inhibitors or angiotensin-receptor blockers and the overall risk of cancer (relative risk [RR] 0.96, 95% confidence interval [CI] 0.90-1.03). We found a decreased risk of cancer associated with use of either medication when we restricted the analyses to cohort and nested case-control studies (RR 0.90, 95% CI 0.83-0.97) or to studies with long-term follow-up of more than five years (RR 0.89, 95% CI 0.83-0.96). In the subgroup meta-analyses by cancer site, a decreased risk was identified for esophageal cancer, whereas an increased risk was found for melanoma and kidney cancer. INTERPRETATION: No significant association was found between the use of ACE inhibitors or angiotensin-receptor blockers and overall risk of cancer. A possible beneficial effect associated with use of either medication was suggested in sensitivity analyses, including those of studies with long-term follow-up. Large randomized controlled trials with long-term follow-up are needed to specifically test the effect of each of these medications on the risk of cancer.
BACKGROUND: Epidemiologic studies have reported inconsistent findings regarding the association between the use of angiotensin-converting-enzyme (ACE) inhibitors or angiotensin-receptor blockers and the risk of cancer. We performed a meta-analysis of observational studies to assess the association. METHODS: We searched MEDLINE, EMBASE and the Cochrane Library to identify studies through January 2011. Two evaluators independently reviewed and selected articles of cohort and case-control studies on the basis of predetermined selection criteria. RESULTS: Of 3970 screened articles, 12 cohort studies and 16 case-control studies were selected for analysis. We found no significant association between the use of ACE inhibitors or angiotensin-receptor blockers and the overall risk of cancer (relative risk [RR] 0.96, 95% confidence interval [CI] 0.90-1.03). We found a decreased risk of cancer associated with use of either medication when we restricted the analyses to cohort and nested case-control studies (RR 0.90, 95% CI 0.83-0.97) or to studies with long-term follow-up of more than five years (RR 0.89, 95% CI 0.83-0.96). In the subgroup meta-analyses by cancer site, a decreased risk was identified for esophageal cancer, whereas an increased risk was found for melanoma and kidney cancer. INTERPRETATION: No significant association was found between the use of ACE inhibitors or angiotensin-receptor blockers and overall risk of cancer. A possible beneficial effect associated with use of either medication was suggested in sensitivity analyses, including those of studies with long-term follow-up. Large randomized controlled trials with long-term follow-up are needed to specifically test the effect of each of these medications on the risk of cancer.
Authors: Sripal Bangalore; Sunil Kumar; Sverre E Kjeldsen; Harikrishna Makani; Ehud Grossman; Jørn Wetterslev; Ajay K Gupta; Peter S Sever; Christian Gluud; Franz H Messerli Journal: Lancet Oncol Date: 2010-11-29 Impact factor: 41.316
Authors: Jeanette Kaae; Heather A Boyd; Anne V Hansen; Hans Christian Wulf; Jan Wohlfahrt; Mads Melbye Journal: Cancer Epidemiol Biomarkers Prev Date: 2010-09-22 Impact factor: 4.254
Authors: L H Lindholm; H Anderson; T Ekbom; L Hansson; J Lanke; B Dahlöf; U de Faire; K Forsén; T Hedner; E Linjer; B Scherstén; P Wester; T Möller Journal: Lancet Date: 2001-08-18 Impact factor: 79.321
Authors: Joan A Largent; Leslie Bernstein; Pamela L Horn-Ross; Sarah F Marshall; Susan Neuhausen; Peggy Reynolds; Giske Ursin; Jason A Zell; Argyrios Ziogas; Hoda Anton-Culver Journal: Cancer Causes Control Date: 2010-06-06 Impact factor: 2.506
Authors: Beatrice Nardone; Sara Majewski; Ashley S Kim; Tina Kiguradze; Estela M Martinez-Escala; Rivka Friedland; Ahmad Amin; Anne E Laumann; Beatrice J Edwards; Alfred W Rademaker; Mary C Martini; Dennis P West Journal: Drug Saf Date: 2017-03 Impact factor: 5.606
Authors: Zachary S Morris; Sandeep Saha; William J Magnuson; Brett A Morris; Jenna F Borkenhagen; Alisa Ching; Gayle Hirose; Vanesa McMurry; David M Francis; Paul M Harari; Rick Chappell; Stuart Tsuji; Mark A Ritter Journal: Cancer Date: 2016-05-20 Impact factor: 6.860
Authors: Elisabeth A George; Navya Baranwal; Jae H Kang; Abrar A Qureshi; Aaron M Drucker; Eunyoung Cho Journal: Cancers (Basel) Date: 2021-05-12 Impact factor: 6.639